Repligen share price today
(NASDAQ: RGEN)

Name: Repligen Share Price Today (NASDAQ: RGEN) - Repligen Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Repligen share price is $167.9 & ₹14,521.67 as on 24 Jan 2025, 2.30 'hrs' IST

$167.9

▲

1.06

(0.64%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Repligen share price in Dollar and Rupees. Guide to invest in Repligen stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Repligen, along with analyst recommendations, forecasts, and comprehensive financials.

Repligen share price movements

Today's Low: $163.00
Today's High: $168.64
$167.90
2.92%
Downside
Day's Volatility :3.34%
Upside
0.44%
52 Weeks Low: $113.50
52 Weeks High: $211.13
$167.90
32.4%
Downside
52 Weeks Volatility :46.24%
Upside
20.48%

Repligen Returns

Period	Repligen Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	23.17%	-5.5%	0.0%
6 Months	18.5%	-4.3%	0.0%
1 Year	-10.06%	1.6%	0.0%
3 Years	-10.01%	9.8%	-11.0%

Repligen Key Statistics

in dollars & INR

Previous Close	$166.84
Open	$164.87
Today's High	$168.64
Today's Low	$163.0
Market Capitalization	$9.3B
Today's Volume	$416.1K
52 Week High	$211.13
52 Week Low	$113.5
Revenue TTM	$639.9M
EBITDA	$100.5M
Earnings Per Share (EPS)	$-0.03
Profit Margin	-0.33%
Quarterly Earnings Growth YOY	-0.83%
Return On Equity TTM	-0.1%

How to invest in Repligen Stock (RGEN) from India?

It is very easy for Indian residents to invest directly in Repligen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Repligen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Repligen or RGEN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Repligen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Repligen shares which would translate to 0.005 fractional shares of Repligen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Repligen, in just a few clicks!

Returns in Repligen for Indian investors in Rupees

Investment Value

₹1,00,000

Repligen investment value today

Current value as on today

₹94,562

Returns

₹5,438

(-5.44%)

Returns from Repligen Stock

₹9,493 (-9.49%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Repligen

367%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Repligen on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 367% more investors are searching Repligen in the last 30 days versus the previous period.

Global Institutional Holdings in Repligen

BlackRock Inc
12.69%
T. Rowe Price Associates, Inc.
11.41%
Vanguard Group Inc
9.00%
State Street Corp
2.90%
Champlain Investment Partners, LLC
2.54%
Sands Capital Management, LLC
2.53%

Analyst Recommendation on Repligen

Buy

78%Buy

21%Hold

0%Sell

Based on 19 Wall street analysts offering stock ratings for Repligen(by analysts ranked 0 to 5 stars)

Based on 19 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Repligen

What analysts predicted

Upside of 14.03%

Target:

$191.46

Current:

$167.90

Insights on Repligen

Price Movement
In the last 1 month, RGEN stock has moved up by 14.5%
Increasing Revenue
Revenue is up for the last 3 quarters, 151.34M → 154.87M (in $), with an average increase of 1.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 3.32M → -654.0K (in $), with an average decrease of 119.7% per quarter
RGEN vs ISRG (1 yr)
In the last 1 year, Intuitive Surgical, Inc. has given 64.4% return, outperforming this stock by 75.2%
RGEN vs ISRG (3 yr)
In the last 3 years, Intuitive Surgical, Inc. has given 126.5% return, outperforming this stock by 135.7%
Price to Sales
ForRGEN every $1 of sales, investors are willing to pay $14.6, whereas for Intuitive Surgical, Inc., the investors are paying $27.5 for every $1 of sales.

Repligen Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$270.2M	↑ 39.28%
Net Income	$21.4M	↑ 28.85%
Net Profit Margin	7.92%	↓ 0.64%

	FY20	Y/Y Change
Revenue	$366.3M	↑ 35.53%
Net Income	$59.9M	↑ 179.88%
Net Profit Margin	16.36%	↑ 8.44%

	FY21	Y/Y Change
Revenue	$670.5M	↑ 83.08%
Net Income	$128.3M	↑ 114.08%
Net Profit Margin	19.13%	↑ 2.77%

	FY22	Y/Y Change
Revenue	$801.5M	↑ 19.54%
Net Income	$186.0M	↑ 44.95%
Net Profit Margin	23.2%	↑ 4.07%

	FY23	Y/Y Change
Revenue	$638.8M	↓ 20.31%
Net Income	$41.6M	↓ 77.64%
Net Profit Margin	6.51%	↓ 16.69%

	FY24	Y/Y Change
Revenue	$632.4M	↓ 1.0%
Net Income	$35.6M	↓ 14.39%
Net Profit Margin	5.63%	↓ 0.88%

	Q2 FY23	Q/Q Change
Revenue	$159.2M	↓ 12.86%
Net Income	$20.1M	↓ 30.4%
Net Profit Margin	12.61%	↓ 3.17%

	Q3 FY23	Q/Q Change
Revenue	$141.2M	↓ 11.29%
Net Income	$18.2M	↓ 9.43%
Net Profit Margin	12.87%	↑ 0.26%

	Q4 FY23	Q/Q Change
Revenue	$155.7M	↑ 10.31%
Net Income	$-25.5M	↓ 240.26%
Net Profit Margin	-16.37%	↓ 29.24%

	Q1 FY24	Q/Q Change
Revenue	$151.3M	↓ 2.82%
Net Income	$2.1M	↓ 108.22%
Net Profit Margin	1.38%	↑ 17.75%

	Q2 FY24	Q/Q Change
Revenue	$154.1M	↑ 1.8%
Net Income	$3.3M	↑ 58.6%
Net Profit Margin	2.16%	↑ 0.78%

	Q3 FY24	Q/Q Change
Revenue	$154.9M	↑ 0.52%
Net Income	$-654.0K	↓ 119.69%
Net Profit Margin	-0.42%	↓ 2.58%

	FY19	Y/Y Change
Profit	$151.1M	↑ 39.85%

	FY20	Y/Y Change
Profit	$209.6M	↑ 38.69%

	FY21	Y/Y Change
Profit	$391.3M	↑ 86.64%

	FY22	Y/Y Change
Profit	$455.7M	↑ 16.47%

	FY23	Y/Y Change
Profit	$284.2M	↓ 37.62%

	FY24	Y/Y Change
Profit	$308.8M	↑ 8.65%

	Q2 FY23	Q/Q Change
Profit	$79.9M	↓ 20.78%

	Q3 FY23	Q/Q Change
Profit	$36.6M	↓ 54.22%

	Q4 FY23	Q/Q Change
Profit	$67.6M	↑ 84.93%

	Q1 FY24	Q/Q Change
Profit	$75.0M	↑ 10.87%

	Q2 FY24	Q/Q Change
Profit	$68.8M	↓ 8.25%

	Q3 FY24	Q/Q Change
Profit	$77.5M	↑ 12.67%

	FY19	Y/Y Change
Operating Cash Flow	$67.2M	↑ 105.11%
Investing Cash Flow	$-205.3M	↑ 1362.62%
Financing Cash Flow	$484.9M	↑ 14131.49%

	FY20	Y/Y Change
Operating Cash Flow	$62.6M	↓ 6.83%
Investing Cash Flow	$-201.4M	↓ 1.91%
Financing Cash Flow	$305.9M	↓ 36.91%

	FY21	Y/Y Change
Operating Cash Flow	$119.0M	↑ 90.05%
Investing Cash Flow	$-221.2M	↑ 9.82%
Financing Cash Flow	$961.0K	↓ 99.69%

	FY22	Y/Y Change
Operating Cash Flow	$172.1M	↑ 44.59%
Investing Cash Flow	$-233.2M	↑ 5.46%
Financing Cash Flow	$-13.3M	↓ 1487.83%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$34.5M	↑ 209.02%
Investing Cash Flow	$64.8M	↓ 787.3%
Financing Cash Flow	$-8.8M	↓ 7.72%

Repligen Technicals Summary

Sell

Neutral

Buy

Repligen is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Repligen Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Repligen Corp	13.54%	18.5%	-10.06%	-10.01%	67.48%
Intuitive Surgical, Inc.	13.67%	38.33%	62.8%	131.11%	222.7%
Alcon Ag	3.14%	-4.92%	16.36%	19.6%	45.42%
West Pharmaceutical Services Inc	4.54%	22.16%	-1.79%	-8.06%	123.72%
Resmed Inc.	6.34%	25.52%	32.72%	6.53%	53.98%
Becton, Dickinson And Company	4.83%	0.26%	0.57%	-7.82%	-14.95%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Repligen Corp	492.86	NA	2.59	1.53	0.0	0.0	NA	35.53
Intuitive Surgical, Inc.	97.13	97.13	4.38	6.92	0.16	0.08	NA	43.75
Alcon Ag	37.84	37.84	3.21	3.03	0.06	0.03	0.0	43.25
West Pharmaceutical Services Inc	51.22	51.22	6.28	6.63	0.18	0.1	0.0	37.96
Resmed Inc.	32.91	32.91	1.82	9.35	0.24	0.13	0.01	35.39
Becton, Dickinson And Company	40.67	40.67	1.09	14.35	0.06	0.03	0.02	89.47

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Repligen Corp	Buy	$9.3B	67.48%	492.86	-0.33%
Intuitive Surgical, Inc.	Buy	$215.2B	222.7%	97.13	28.51%
Alcon Ag	Buy	$44.2B	45.42%	37.84	11.89%
West Pharmaceutical Services Inc	Buy	$25.0B	123.72%	51.22	17.37%
Resmed Inc.	Buy	$36.4B	53.98%	32.91	23.15%
Becton, Dickinson And Company	Buy	$69.0B	-14.95%	40.67	7.13%

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Organization	Repligen
Employees	1783
CEO	Mr. Anthony J. Hunt
Industry	Health Technology

Management People of Repligen

Name	Title
Mr. Anthony J. Hunt	Executive Chair
Mr. Olivier Loeillot	President, CEO & Director
Mr. Jason K. Garland	CFO & Chief Compliance Officer
Mr. James R. Bylund	Chief Operating Officer
Mr. Ralf Kuriyel	Senior Vice President of Research & Development
Mr. Keith Lee Robinson	Chief Information Officer
Ms. Sondra S. Newman	Global Head of Investor Relations
Ms. Kimberly A. Cornwell	Global Head of Legal
Mr. Neil Whitfield	VP & Global Head of Sales
Ms. Teresa Ferragamo	Senior Director of Marketing

Important FAQs about investing in Repligen (RGEN) from India :

What is Repligen share price today?

Repligen share price today stands at $167.90, Open: $164.87 ; Previous Close: $166.84 ; High: $168.64 ; Low: $163.00 ; 52 Week High: $211.13 ; 52 Week Low: $113.50. The stock opens at $164.87, after a previous close of $166.84. The stock reached a daily high of $168.64 and a low of $163.00, with a 52-week high of $211.13 and a 52-week low of $113.50.

Can Indians buy Repligen shares?

Yes, Indians can invest in the Repligen (RGEN) from India.

With INDmoney, you can buy Repligen at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Repligen at zero transaction cost.

How can I buy Repligen shares from India?

It is very easy to buy Repligen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Repligen be purchased?

Yes, you can buy fractional shares of Repligen with INDmoney app.

What are the documents required to start investing in Repligen stocks?

To start investing in Repligen, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.